Skip to main content

Table 1 Overview of subjects investigated

From: Antibodies reacting with JCPyV_VP2 _167-15mer as a novel serological marker for JC polyomavirus infection

Variable

Screening study (n = 50)

Evaluation study (n = 204)

Gender, n (%)

   
 

Male

22 (44%)

97 (48%)

 

Female

28 (56%)

107 (52%)

 

Age, median (Min-Max)

40.5 (23–59)

42 (19–66)

Race, ethnicity, n (%)

  
 

White

38 (76%)

201 (98.5%)

 

Black

3 (6%)

0 (0%)

 

Asian

8 (16%)

2 (1%)

 

Other/unknown

1 (2%)

1 (0.5%)

JCPyV VP1 serology, n (%)

  
 

Positive

36 (72%)

156 (57%)

 

Negative

14 (28%)

88 (43%)

JCPyV Viruria, n (%)

  
 

Positive*

13 (26%)

50 (25%)

 

Negative

37 (74%)

154 (75%)

BKPyV VP1 serology, n (%)

  
 

Positive

n.d.

178 (88%)

 

Negative

n.d.

24 (12%)

JCPyV_VP2_167-15mer serology, n (%)

  
 

Positive

32 (64%)

165 (81%)

 

Negative

18 (36%)

39 (19%)

  1. *All JCPyV viruric subjects were part of the JCPyV VP1 seropositive subgroup.